Pharmaceutical

Galecto downsizes by 70% following Phase II trial failure

Apart from the workforce cuts, the company is also considering asset divestment and mergers as part of a strategic review.

Sep 27, 2023 - 20:00
Galecto downsizes by 70% following Phase II trial failure
Apart from the workforce cuts, the company is also considering asset divestment and mergers as part of a strategic review.
Read the original article

Tags:

Previous Article

Avalyn raises $175m in funding to develop inhaled IPF drugs

Next Article

Novo Nordisk and Evotec launch translational drug discovery accelerator

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

After Amylyx ALS trial failure, patients share disappointment and fear — but some hope

After Amylyx ALS trial failure, patients share disappoi...

Mar 13, 2024

Nona Biosciences partners with Alaya.bio for CAR-T therapy

Nona Biosciences partners with Alaya.bio for CAR-T therapy

Jul 16, 2024

STAT+: Drug industry payments to eye docs boosted Medicare spending on pricier treatments

STAT+: Drug industry payments to eye docs boosted Medic...

Sep 28, 2023